On Tuesday, May 29, U.S. District Judge Sue L. Robinson ruled that “Teva Pharmaceuticals USA Inc. and Par Pharmaceutical Inc. infringed two Pronova Biopharma Norge AS patents when they filed applications to sell a generic version of triglyceride-lowering drug Lovaza® in 2009.” The decision detailed that Teva and Par had infringed two of Pronova’s patents “ruling that the defendants had failed to prove the patents were invalid and unenforceable.” Morten Jurs, CEO of Pronova, said the company was pleased with the decision. Finnegan represented Pronova in this matter.
Award/Ranking
Finnegan Recognized as Leader in Intellectual Property Litigation at 2013 LMG Life Sciences Awards
September 26, 2013
Media Mention
Revival of Aesthetic Functionality Doctrine Imperils Non-Traditional Marks, Panelists Say
March 13, 2012
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.